History
deep cementopathia parodontitis marginalis progressiva Periodontosis Juvenile periodontitis
elevated levels of Actinobacillus actinomycetemcomitans Causes for localized nature 1. Host immune response 2. Antagonistic bacteria 3. Loss of virulence 4. Cemental defects
C/F:
Rapid rate of periodontal destruction distolabial migration of the maxillary incisors increasing mobility of the first molars, Root sensitivity, deep, dull, radiating pain Periodontal abscesses Regional lymph node enlargement
R/F:
Vertical loss of alveolar bone around the first molars and incisors arc-shaped loss of alveolar bone
C/F:
Period of Advanced Destruction Severe, acutely inflamed tissue, often proliferating, ulcerated, and fiery red Bleeding - spontaneously /with slight stimulation. Suppuration Attachment and bone are actively lost
Period of Quiescence pink, free of inflammation, stippling deep pockets bone level remains stationary
R/F:
severe bone loss associated with the minimal number of teeth, advanced bone loss affecting the majority of teeth in the dentition
Risk Factors
Microbiologic A. actinomycetemcomitans primary pathogen Immunologic functional defects of polymorphonuclear leukocytes (PMNs), monocytes hyperresponsive monocytes
3. Antibiotic therapy presence of A. actinomycetemcomitans in the tissues systemic tetracycline 250 mg, four times daily 1 week. Doxycycline 200 mg 1st day 100 mg, once daily 1 week Chlorhexidine rinses
Combination Therapy
metronidazole/amoxicillin (Augmentin) metronidazole/doxycycline metronidazole/ ciprofloxacin amoxicillin/doxycycline A. actinomycetemcomitansassociated periodontitis recurrent periodontitis microflora associated with enteric rods and pseudomonads A. actinomycetemcomitansand/or Porphyromonas gingivalis-associated periodontitis
Host Modulation
a. Sub-antimicrobial dose drug E.g: Periostat (doxyxline hyclate, 20 mg) b. NSAIDs E.g: flurbiprofen, indomethacin, and naproxen
Restorative Treatment
Plan for future tooth loss. removable partial dentures
monitor and observe the patient's overall physical status. Close collaboration between members of the treatment team, which includes i. the periodontist, ii. the general dentist, iii. the dental hygienist, and iv. the patient's physician frequent monitoring cycle